A pioneering team at St Jude Children's Research Hospital in the US say they successfully treated a child diagnosed with SMA ...
Le gel de l'aide étrangère par le gouvernement américain a bouleversé la chaîne d'approvisionnement en produits médicaux ...
Roche dévoile une technologie exclusive et révolutionnaire de séquençage par expansion , qui 'offre un séquençage ...
a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam ...
A mother was given SMA treatment Evrysdi during pregnancy, and her child with SMA, now 2.5, has not shown any signs of the ...
Basel: Roche, announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an ...
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
Medpage Today on MSN2d
First-Ever Prenatal Treatment for Spinal Muscular Atrophy Shows PromiseThe first prenatal therapy for spinal muscular atrophy (SMA) showed promising results, a case report indicated. More than 2 ...
The biotech industry is ripe with great investment opportunities due to technological advancements such as artificial ...
Roche is already an established player in diseases that affect movement, with therapies on the market for multiple sclerosis (Ocrevus) and spinal muscular atrophy (Evrysdi) and a pipeline of new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback